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Abstract
Background: Several recent studies have reported that patients with metastatic colorectal cancer (CRC) whose
primary tumor is located in left side of the colon have more favorable responses to anti-epidermal growth factor
receptor (EGFR) antibody therapy than those with right-sided tumors. However, the mechanism for this
phenomenon is unknown.
Methods: Fifty-two cases of primary CRC with liver metastases were analyzed in this retrospective study. The mRNA
levels of 19 signal transduction genes in both primary tumor and liver metastases were measured by real-time
reverse transcription polymerase chain reaction. The purposes of this study were (1) to determine the
correspondence between signal transduction gene expressions in primary tumors and corresponding liver
metastases, and (2) to determine whether expression levels of these genes differ by primary tumor location.
Results: mRNA expression levels of 14 of 19 signal transduction genes, including PTEN, ERBB2, MET, HGF, AREG, and
EREG, showed significant correlations between the primary tumor and corresponding liver metastases. When the
mRNA levels of the primary tumors were compared by tumor location, only PTEN mRNA expression differed
significantly between left and right-sided CRC (median PTEN expression: left 1.00 vs. right 1.68; p = 0.017). When
rectal cancers were separated from left-sided colon cancers, PTEN mRNA levels increased progressively from rectum
to right-sided colon (median; rectum 0.84, left colon 1.23, right colon 1.68, p = 0.013). PTEN mRNA expression in liver
metastases also differed significantly according to primary tumor location (median; left 0.92 vs. right 1.27, p = 0.048).
There was no difference in overall survival between patients with high versus low levels of PTEN mRNA (p = 0.59).
Conclusions: Our data suggest that the PIK3/AKT/mTOR pathway is more active in left- than right-sided CRC, which
provides a possible explanation for the fact that efficacy of anti-EGFR therapy differs by location of primary tumor.
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Background
Recent progress in chemotherapy for metastatic colorec-
tal cancer (mCRC) has been remarkable, with many
novel drugs including molecular targeted agents having
been developed. Anti-epidermal growth factor receptor
(EGFR) antibody drugs, such as cetuximab and panitu-
mumab, often combined with cytotoxic drugs, are now
widely used as front-line chemotherapy for Ras wild-
type mCRC, and are demonstrating promising results [1,
2]. Several recently published studies have demonstrated
an association between the effect of anti-EGFR antibody
and the location of the primary tumor in patients with
mCRC. Brule et al. reported that, in the NCIC CO.17
study, patients with left-sided tumors had significantly
longer progression-free survival when treated with
cetuximab compared with best supportive care, whereas
those with right-sided did not [3]. Einem et al. reported
that, in the AIO KRK-0104 trial, left-sided tumors were as-
sociated with significantly longer overall and progression-
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free survival than right-sided tumors among patients with
KRAS wild-type CRC when treated with cetuximab as first-
line treatment [4].
The left and right colon have different embryologic ori-
gins, the left colon being from the foregut and the right
from the midgut, and different blood supplies. Therefore,
as first proposed by Bufills et al. [5], left- and right-sided
colon cancers are distinct genetic entities. However, no
molecular biomarkers that elucidate the reason(s) for the
differences in the effects of these agents according to
tumor location have yet been identified.
Liver metastases are the main cause of death in most
patients with mCRC. Because controlling liver metasta-
ses is considered essential in the treatment of mCRC, it
is reasonable to expect that the level of mRNA expres-
sion of molecular target genes in liver metastases would
be the best predictor of therapy benefit. However, in
many—if not most—cases, only biopsies of the patient’s
primary tumor are readily available for analysis. There-
fore, it is important to investigate the relationship be-
tween levels of response determinants in the primary
tumor and in the corresponding liver metastases to de-
termine whether analysis of biopsies of the primary
tumor is useful for prediction of tumor response.
In this study, we have analyzed the mRNA expression
levels of 19 signal transduction genes from both the pri-
mary tumors and corresponding liver metastases of 52
patients with CRC and resectable liver metastases. The
purposes of this study were (1) to determine the rela-
tionship between signal transduction gene expressions in
primary tumors and corresponding liver metastases, and
(2) to determine whether expression levels of these
genes differ by location of the primary tumor site in pa-
tients with mCRC.
Methods
Patients and samples
Data from 52 cases of primary CRC with liver metastases
were analyzed in this retrospective study (35 men and 17
women; median age, 61.5 years (range, 32–91 years). The me-
tastases were synchronous in 33 patients and metachronous
in 19. The patients had undergone surgical resection of
primary colorectal adenocarcinomas and liver metastases
between 1995 and 2007 in the Department of Gastro-
enterology, Tokyo Women’s Medical University, Tokyo,
Japan. All patients were Japanese and all had given their
written informed consent according to the institutional
regulations. Relevant characteristics of the 52 patients are
shown in Table 1. They were classified as having right-
sided CRC if the primary tumor was located in the cecum,
ascending colon, hepatic flexure, or transverse colon, and
left-sided CRC if the tumor site was within the splenic
flexure, descending colon, sigmoid colon, or rectum.
This study was approved by the Ethics Committee of
Tokyo Women’s Medical University and performed in
accordance with the Declaration of Helsinki.
Microdissection
Formalin-fixed, paraffin-embedded tumor specimens
were cut into 10 μm thick serial sections. For patho-
logical diagnosis, one slide was stained with hematoxylin
and eosin and evaluated by a pathologist. Manual micro-
dissection using a scalpel was performed if the histology
was homogeneous and contained more than 90 % cancer
cells. For all other samples, laser-capture microdissec-
tion (P.A.L.M. Microlaser Technologies AG, Munich,
Germany) was performed to ensure that only tumor cells
were dissected.
RNA isolation and cDNA synthesis
Isolation of RNA from formalin-fixed paraffin-embedded
(FFPE) specimens was performed using an RNeasy FFPE
Kit (Qiagen, Tokyo, Japan) according to the manufac-
turer’s instructions. cDNA was converted from the total
RNA yielded, using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Tokyo, Japan).
Reverse transcription-PCR
cDNA was pre-amplified using a Taqman PreAmp Mas-
ter Mix Kit (Applied Biosystems) according to the man-
ufacturer’s instructions. mRNA expression of 19 signal
transduction genes and a single internal reference gene
Table 1 Patient Characteristics
Gender M/F 35/17 Lymph node pN0 16
Age Median (range) 61.5 (32–91) pN1,N2 36
Location of primary tumor rectum 15
Pathology Well differentiated 40 left colon 20
Moderate-poor 10 right colon 17
Mucinous 2 Liver metastases synchronous 33
Depth pT2 1 metachronous 19
pT3 7 KRAS wild 26
pT4 44 (codon12,13) mutant 23
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(beta-2-macrogloblin) were measured by a fluorescence-
based real-time polymerase chain reaction (PCR) detec-
tion method (StepOne real-time PCR system, Applied
Biosystems). A list of the 19 genes and primers/probes
information for the Taqman Gene Expression Assays
(Applied Biosystems) is provided in Table 2. The PCR
reaction mixture consisted of 10 μL of Taqman Fast Uni-
versal PCR Master Mix, No UNG (Applied Biosystems),
5 μL of pre-amplified cDNA sample, 1 μL of Taqman
Gene Expression Assays primers and probe (20×), and
3 μL of nuclease-free water. Cycling conditions were 95 °
C for 20 s, followed by 40 cycles at 95 °C for 1 s and
60 °C for 20 s. The threshold cycle (CT) value for each
gene was determined by SDS software v1.2 (Applied Bio-
systems). The delta-CT(ΔCT) value, which is the differ-
ence between the CT value of the target gene and that of
the endogenous control gene, was calculated by the
same software. Delta-ΔCT (ΔΔCT), which is the differ-
ence in the ΔCT value for each sample and the highest
ΔCT value as a calibrator, was also calculated and the 2-
ΔΔCT number used for relative mRNA quantification.
Median values were used as the cut-off values to div-
ide strong from weak expression.
Screening for KRAS mutation
DNA was extracted from the FFPE specimens using a
Qiamp DNA FFPE tissue Kit (Qiagen, Tokyo, Japan)
according to the manufacturer’s instructions. KRAS codon
12,13 mutations were measured by direct-sequencing
method, as previously described [6].
Statistical analysis
Median mRNA levels for left- and the right-sided tu-
mors, and PTEN mRNA levels by KRAS status were
compared using the Wilcoxon signed-rank test. The cor-
relation between the mRNA levels of primary tumors
and corresponding liver metastases was assessed using
Spearman’s rank correlation. KRAS mutation frequency
was compared between left- and the right-sided tumors
using Fisher’s exact test. The Kaplan–Meier method was
used to construct survival curves and the log-rank test
for statistical analysis. Overall survival was defined as
the time from the day of primary tumor resection to
death from any cause. Statistical analyses were per-
formed using JMP 10 (SAS Institute, Cary, NC, USA).
Statistical significance was recognized at P-values of less
than 0.05. All values are two-sided.
Results
Comparison of mRNA expression in primary tumors and
corresponding liver metastases
Correlations between mRNA expression levels of 19
genes in primary tumors and the corresponding liver
metastases are shown in Table 3. Significant correlations
Table 2 Target gene characteristics
Gene symbol Gene name Location Primer No.
AREG amphiregulin 4q13.3 Hs00950669_m1
BTC betacellulin 4q13.3 Hs01101204_m1*
EGF epidermal growth factor 4q25 Hs01099999_m1
EGFR epidermal growth factor receptor 7p12 Hs00193306_m1
ERBB2 erb-b2 receptor tyrosine kinase 2 17q12 Hs01001580_m1*
ERBB3 erb-b2 receptor tyrosine kinase 3 12q13 Hs00176538_m1*
ERBB4 erb-b2 receptor tyrosine kinase 4 2q33.3-q34 Hs00955525_m1*
EREG epiregulin 4q13.3 Hs00914312_m1
HBEGF heparin-binding EGF-like growth factor 5q23 Hs00181813_m1*
HGF hepatocyte growth factor 7q21.1 Hs00300159_m1*
IGF1 insulin-like growth factor 1 12q23.2 Hs01547656_m1*
IGF1R insulin-like growth factor 1 receptor 15q26.3 Hs00609566_m1
IGF2 insulin-like growth factor 2 11p15.5 Hs01005962_m1
IGF2R insulin-like growth factor 2 receptor 6q26 Hs00181419_m1*
MET met proto-oncogene 7q31 Hs01565584_m1*
MST1 macrophage stimulating 1 3p21 Hs00360684_m1
MST1R macrophage stimulating 1 receptor 3p21.3 Hs00899925_m1*
PTEN phosphatase and tensin homolog 10q23.3 Hs02621230_s1
TGFA transforming growth factor, alpha 2p13 Hs00608187_m1
B2M beta 2-microglobulin 15q21-q22.2 Hs99999907_m1
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were identified for AREG (p = 0.023), EREG (p = 0.0022),
EGF (p = 0.0057), EGFR (p = 0.0007), ERBB2 (also
known as HER2) (p < 0.0001), ERBB3 (p = 0.044), HBEGF
(p = 0.014), HGF (p = 0.0023), MET (p = 0.0005), IGF1R
(p < 0.0001), IGF2R (p < 0.0001), MST1R (p = 0.0069),
PTEN (p = 0.0003), and TGFA (p < 0.0001), whereas no
significant correlations were identified for BTC, ERBB4,
IGF, IGF2, and MST1.
Comparison of mRNA levels and KRAS status between
left- and right-sided CRC
Thirty-five patients were had left-sided and 17 right-sided
CRCs. The primary tumor mRNA expression levels of 19
genes were compared between left- and right-sided can-
cers: only PTEN mRNA expression differed significantly
(median; left 1.00 vs. right 1.68; p = 0.017) (Fig. 1). When
rectal (n = 15) were separated from left-sided colon CRCs
(n = 20), PTEN mRNA levels progressively increased from
rectum to right-sided colon (median; rectum 0.84, left
colon 1.23, right colon 1.68; p = 0.013) (Fig. 2). PTEN
mRNA expression in liver metastases also differed signifi-
cantly according to primary tumor location (median; left
0.92 vs. right 1.27; p = 0.048) (Fig. 3).
The correlation of PTEN mRNA expression in
primary tumors and corresponding liver metastases is
shown in Fig. 4. The Spearman correlation coefficient
was 0.48 (p = 0.0003).
There was a non-significant tendency toward a higher
frequency of KRAS codon 12,13 mutation in right-
sided CRC (KRAS mutation %: left 37.5 % vs. right
64.7 %; p = 0.082).
Amounts of PTEN mRNA in the primary tumor did
not differ significantly between patients with KRAS wild
and mutant genes (PTEN median 1.22 vs. 1.00, p = 0.21).
PTEN expression and overall survival
When the median value of PTEN mRNA levels in the
primary tumor was used as a cut-off line, there was no
difference in overall survival between patients with high
and low levels of PTEN mRNA (p = 0.59).
Discussion
Several recent several studies have reported that the lo-
cation of CRCs is associated with response to anti-EGFR
antibody [3, 4, 7, 8]. All these studies found that left-
sided CRCs are associated with more favorable responses
and prognosis than are right-sided. However, the mecha-
nism(s) for this phenomenon has not been identified.
In this study, only PTEN mRNA levels differed signifi-
cantly between left- and right-sided CRCs. PTEN mRNA
levels progressively increased from rectum to right-sided
colon. PTEN is a downstream inhibitor of the PI3K/Akt/
mTOR pathway, one of the EGFR pathways, which mod-
ulates cell proliferation and survival [9]. Loss of the
PTEN tumor suppressor function has been observed in
various cancers, such as those of breast, prostate, thy-
roid, and endometrial origin [10]. Our finding of weaker
PTEN expression in left- than right-sided side CRC indi-
cates that the PI3K pathway is more active in left- than
right-sided CRC. Johnson et al. reported that, in 154 pa-
tients with CRC, expression of PI3K/Akt/mTOR path-
way components as measured by immunohistochemistry
was stronger in left-than right-sided CRCs [11], which
supports our data. If the PI3K-mTOR pathway is more
active in left-sided lesions, it is unsurprising that block-
ing the EGFR pathway with anti-EGFR antibody seems
to be more effective in left- than right-sided CRCs.
Although PTEN is known to have germline mutation
and deletion by allelic loss [12–15], it has been suggested
that PTEN may be inactivated by mechanisms other
than mutations and/or deletions. Goel et al. reported
that hypermethylation of the PTEN promoter correlates
significantly with either decreased or complete loss of
PTEN protein expression [10]. Several studies have
found that PTEN loss and PIK3CA mutation are associ-
ated with resistance to anti-EGFR therapy [14, 16, 17].
However, others have reported that PTEN and PIK3CA
mutation have no relationship with the outcome of anti-
EGFR therapy [18, 19]. The usefulness of PIC3CA and
Table 3 Correlation between mRNA levels in primary tumors
and liver
Gene symbol Spearman rank-order
correlation coefficient (Rs)
p-value
AREG 0.31 0.023*
EREG 0.42 0.0022*
BTC 0.16 0.27
EGF 0.38 0.0057*
EGFR 0.46 0.0007*
ERBB2 0.55 <0.0001*
ERBB3 0.28 0.044*
ERBB4 0.11 0.42
HBEGF 0.34 0.014*
HGF 0.41 0.0023*
MET 0.47 0.0005*
IGF 0.23 0.094
IGF1R 0.61 <0.0001*
IGF2 0.051 0.72
IGF2R 0.65 <0.0001*
MST1 0.054 0.70
MST1R 0.37 0.0069*
PTEN 0.48 0.0003*
TGFA 0.55 <0.0001*
* statistically significant (p < 0.05)
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PTEN as biomarkers is still controversial; they appear to
be less reliable biomarkers than RAS or BRAF.
Mao et al. pooled data from eight studies and found a
concordance rate of 71.7 % for PTEN expression in pri-
mary CRCs and their metastases [20]. This concordance
rate is relatively small compared with those for KRAS
mutation (92 %), BRAF mutation (96.8 %), and PIK3CA
mutation (93.9 %). Although immunohistochemistry
(IHC) was used in most of the PTEN studies included in
this meta-analysis, in our study we used mRNA expres-
sion levels as measured by quantitative real-time reverse
transcription polymerase chain reaction. This quantita-
tive method showed a relatively strong correlation be-
tween primary CRCs and their liver metastases. Hocking
et al. used Taqman copy number variation and IHC to
assess loss of PTEN function in 51 patients with CRC
and reported a concordance rate of 68 % between Taq-
man copy number and IHC in assessment of PTEN loss
[21]. Reported findings seem to vary between method-
ologies: standardized assessment of PTEN function is re-
quired to clarify the role of PTEN as a biomarker.
We found significant correlations of mRNA expression
between primary tumor and liver metastates for 14
genes, but not for the other five. A recent study showed
that HER2- (ERBB2) positive CRC has favorable re-
sponses to trastuzumab, which is an anti-HER2 antibody
[22]. Even when a resected primary tumor is HER2-
positive, if HER2 expression differs between the primary
and metastatic tumors, different strategies should be
considered for treating the metastatic lesions. However,
our data indicate a strong correlation (p < 0.0001) be-
tween mRNA expression of ERBB2 in primary tumors
Fig. 1 PTEN mRNA expression in primary tumor by tumor location PTEN mRNA levels are significantly higher in right- than in left-sided colorectal
cancer (median; left 1.00 vs. right 1.68, p = 0.017)
Fig. 2 PTEN mRNA expression in primary tumor by location in rectum, left-sided colon, and right-sided colon PTEN mRNA levels progressively
increase from rectum to right-sided colon (median; rectum 0.84, left colon 1.23, right colon 1.68, p = 0.013)
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and liver metastases, which suggests that anti-HER2
drugs can be used to treat metastases when the primary
tumor is HER2-positive. MET is a tyrosine kinase recep-
tor in the membrane surface, and HGF is the main lig-
and of MET. Although rilotumumab (an anti-HGF
antibody) and onartuzumab (an anti-MET antibody)
have not been found to confer survival benefit in non-
small cell lung or gastric cancers [23–25], rilotumumab
reportedly showed survival benefit when used with pani-
tumumab in a phase II trial [26]. MET-positive cancer
shows better results than MET-negative cancer when
treated with MET inhibitor [27]: MET expression is
regarded as a useful biomarker of anti-MET treatment.
According to our data, MET and HGF gene expression
in primary CRCs and their metastases is significantly
correlated, which is helpful regarding choice of treat-
ment for liver metastases.
Several published studies have reported that the
right-sided colon more frequently has KRAS and BRAF
mutations [28–31]. Although we did not analyze BRAF
mutational status, our data showed a tendency to higher
frequency of KRAS exon 2 mutation; however, this was
not statistically significant because of the small sample
size. Maus et al. reported that BRAF mutations are more
common in right-sided colon, suggested that the predilec-
tion of BRAF mutation for the right-sided colon partly
Fig. 3 PTEN mRNA expression in liver metastases by location of primary tumor PTEN mRNA levels are significantly higher in liver metastases from
right-sided colon cancer than in those from left-sided colorectal cancer (median; left 0.92 vs. right 1.27, p = 0.048)
Fig. 4 Correlation of PTEN mRNA expression between primary tumor and liver metastases. There is a significant correlation between PTEN mRNA
expression in primary tumor and liver metastases. Spearman’s correlation coefficient 0.48 (p = 0.0003)
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reflects the high microsatellite instability in this region be-
cause such tumors more frequently have BRAF mutations
[28]. Recently, Guinney et al. reported four consensus mo-
lecular subtypes in colorectal cancer, one of which was
characterized by hypermutation, microsatellite instability
and strong immune activation and comprised 14 % of colo-
rectal cancers [32]. Pembrolizumab, an anti-programmed
death 1 (PD-1) immune checkpoint inhibitor, was recently
reported to induce remarkable responses in microsatellite
unstable colorectal cancers [33]. These data indicate that
right-sided colon cancer has more potential to respond to
PD-1 inhibitors, in contrast with data indicating that left-
sided colon cancer may be more likely to respond to anti-
EGFR agents. Tumor location may soon become an im-
portant factor when deciding treatment strategy.
Conclusions
In summary, our data show that PTEN mRNA expres-
sion differs between left- and right-sided CRCs. We also
demonstrated significant correlations between expres-
sion of 14 of 19 signal transduction genes in primary tu-
mors and their liver metastases. These data will help in
determining why the effects of anti-EGFR antibody differ
according to tumor location.
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